Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Lynch Karen S reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Karen S. Lynch reported a stock award of 499 shares of common stock on May 20, 2026, recorded at $0.0000 per share. After this grant, she directly owns 1,159 common shares. The filing also reports 76 additional common shares held indirectly through a living trust.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a stock grant of 499 shares of Common Stock as compensation, not an open-market purchase. The shares were awarded at a stated price of $0.00 per share, increasing his directly held position to 2,602 shares following the transaction.
JOHNSON JENNIFER M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Jennifer M. Johnson reported receiving a grant of 499 shares of Common Stock on May 20, 2026. The award was recorded at a price of $0.00 per share, indicating it was part of her director compensation rather than an open-market purchase. After this grant, she directly holds a total of 1,403 shares of Thermo Fisher Scientific common stock.
Jacks Tyler reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Tyler Jacks received a grant of 499 shares of common stock on May 20, 2026. The award was granted at no cash cost per share and increased his directly held position to 9,462 shares. This is a routine compensation-related equity grant rather than an open-market purchase.
HARRIS C MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Harris C. Martin received a grant of 499 shares of Common Stock on May 20, 2026 at no cash cost. This compensation-related award increased his direct holdings to 9,532 shares. The filing does not report any open-market buying or selling.
THERMO FISHER SCIENTIFIC INC. director Ruby R. Chandy received a grant of 499 shares of Common Stock on May 20, 2026 at no cost as compensation. Following this award, Chandy directly holds 3,463 shares, indicating a routine, non-market acquisition rather than an open-market purchase or sale.
Thermo Fisher Scientific director Nelson Chai received a stock grant of 499 shares of Common Stock. The shares were acquired at a stated price of $0.00 per share, indicating a compensation-related award rather than an open-market purchase. Following this grant, Chai directly holds 15,316 shares of Thermo Fisher Scientific Common Stock.
Thermo Fisher Scientific reported Q1 2026 revenue of $11.01B, up 6% year over year, with organic revenue growth of 1%. GAAP operating income was $1.86B and diluted EPS rose to $4.43 from $3.98, helped by a low 4.0% effective tax rate.
The company generated free cash flow of $825M and ended the quarter with $3.25B in cash and $43.16B of total debt. It closed the $9.10B acquisition of Clario to expand clinical research offerings and agreed to sell its microbiology business for about $1.08B. Thermo Fisher also repurchased $3.0B of stock and recorded $49M of restructuring costs, with about $290M of additional actions identified, mainly in Laboratory Products and Biopharma Services.
Thermo Fisher Scientific Inc Schedule 13G: Vanguard Capital Management reports beneficial ownership of 28,008,822 shares of Thermo Fisher common stock, representing 7.53% of the class as of 03/31/2026. The filing states these holdings include securities held by Vanguard funds and managed accounts where Vanguard affiliates exercise dispositive power.
Thermo Fisher Scientific President & COO Gianluca Pettiti sold 400 shares of Common Stock in an open-market transaction. The sale occurred on April 27, 2026 at a price of $462.66 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on September 12, 2025. After this sale, Pettiti continues to hold 25,050.832 shares of Thermo Fisher Scientific Common Stock directly.